Preparation, characterization, and in vivo evaluation of perphenazine-loaded nanostructured lipid carriers for oral bioavailability improvement

References

• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• Lammer E, Klingelhöfer D, Bendels M, et al. Development of the global schizophrenia research under epidemiological and socio-economic influences. Schizophr Res. 2018;199:458–460.
   PubMed Web of Science ®Google Scholar
• Ayano G. Schizophrenia: a concise overview of etiology, epidemiology diagnosis and management: review of literatures. J Schizophrenia Res. 2016;3(2):2–7.
   Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABA. Curr Opin Investig Drugs. 2010;11(1):92–100.
   PubMedGoogle Scholar
• Mondal S, Kumar CR, Pavan TS, et al. New spectrophotometric techniques for the estimation of perphenazine in bulk drug form. J Drug Deliv Ther. 2019;9(2-s):466–473.
   Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080–2089.
   PubMed Web of Science ®Google Scholar
• Hartung B, Sampson S, Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst Rev. 2015;2015(3):CD003443.
   Google Scholar
• Turunen E, Mannila J, Laitinen R, et al. Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. J Pharm Pharmacol. 2011;63(1):19–25.
   PubMed Web of Science ®Google Scholar
• Beg S, Swain S, Rizwan M, et al. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv. 2011;8(6):691–702.
   PubMed Web of Science ®Google Scholar
• Wang L, Zeng F, Zong L. Development of orally disintegrating tablets of perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex. Pharm Dev Technol. 2013;18(5):1101–1110.
   PubMed Web of Science ®Google Scholar
• Bruni G, Maggi L, Tammaro L, et al. Electrospun fibers as potential carrier systems for enhanced drug release of perphenazine. Int J Pharm. 2016;511(1):190–197.
   PubMedGoogle Scholar
• Baboota S, Mustafa AG, Sahni JK, et al. Mechanistic approach for the development of ultrafine oil-water emulsions using monoglyceride and blends of medium and long chain triglycerides: enhancement of the solubility and bioavailability of perphenazine. J Excipients Food Chem. 2016;4(1):1099.
   Google Scholar
• Dong B, Hadinoto K. Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine. Drug Dev Ind Pharm. 2017;43(6):996–1002.
   PubMed Web of Science ®Google Scholar
• Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm. 2013;453(1):215–224.
   PubMed Web of Science ®Google Scholar
• Gaba B, Fazil M, Ali A, et al. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv. 2015;22(6):691–700.
   PubMed Web of Science ®Google Scholar
• Sharma A, Baldi A. Nanostructured lipid carriers: a review. J Dev Drugs. 2018;7(191):2.
   Google Scholar
• Dening TJ, Rao S, Thomas N, et al. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release. 2016;223:137–156.
   PubMed Web of Science ®Google Scholar
• Natarajan J, Karri V, Anindita D. Nanostructured lipid carrier (NLC): a promising drug delivery system. Glob J Nano. 2017;1(5):1–6.
   Google Scholar
• Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–191.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Sharma J, Singh M, et al. Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs. Acta Pharm Sci. 2018;56(3):27.
   Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313.
   PubMed Web of Science ®Google Scholar
• Barkat MA, Rizwanullah M, Beg S, et al. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech. 2019;20(2):87.
   PubMed Web of Science ®Google Scholar
• Hrdlička A, Ďurd'ová Z, Hadašová E. Solid-phase extraction of perphenazine from blood serum for high performance liquid chromatographic analysis. J Liq Chromatogr Relat Technol. 1997;20(6):935–942.
   Web of Science ®Google Scholar
• Bagherpour S, Alizadeh A, Ghanbarzadeh S, et al. Preparation and characterization of betasitosterol-loaded nanostructured lipid carriers for butter enrichment. Food Biosci. 2017;20:51–55.
   Web of Science ®Google Scholar
• Sadegh Malvajerd S, Azadi A, Izadi Z, et al. Brain delivery of curcumin using solid lipid nanoparticles and nanostructured lipid carriers: preparation, optimization, and pharmacokinetic evaluation. ACS Chem Neurosci. 2019;10(1):728–739.
   PubMed Web of Science ®Google Scholar
• Shahparast Y, Eskandani M, Rajaei A, et al. Preparation, physicochemical characterization and oxidative stability of omega-3 fish oil/α-tocopherol-co-loaded nanostructured lipidic carriers. Adv Pharm Bull. 2019;9(3):393–400.
   PubMed Web of Science ®Google Scholar
• Jawahar N, Hingarh PK, Arun R, et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int J Biol Macromol. 2018;110:269–275.
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Ibrahim HM, Ahmed MA, et al. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv. 2017;24(1):932–941.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Suihko E, Bjorkqvist M, et al. Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm. 2010;36(5):601–613.
   PubMed Web of Science ®Google Scholar
• Tillmann S, Wegener G. Syringe-feeding as a novel delivery method for accurate individual dosing of probiotics in rats. Benef Microbes. 2018;9(2):311–315.
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88(1):160–168.
   PubMed Web of Science ®Google Scholar
• Pedernera C, Ruiz JL, Castells G, et al. HPLC quantification of perphenazine in sheep plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1–2):308–312.
   PubMed Web of Science ®Google Scholar
• Bahari LAS, Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull. 2016;6(2):143–151.
   PubMed Web of Science ®Google Scholar
• Nautyal U, Singh R, Singh S, et al. Nanostructure lipid carrier (NLC): the new generation of lipid nanoparticles. Asian Pac J Health Sci. 2015;2(2):76–93.
   Google Scholar
• Shah R, Eldridge D, Palombo E, et al. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25(1):59–75.
   Google Scholar
• Douglas S, Illum L, Davis S. Particle size and size distribution of poly (butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. J Colloid Interface Sci. 1985;103(1):154–163.
   Web of Science ®Google Scholar
• Bodratti AM, Alexandridis P. Formulation of poloxamers for drug delivery. J Funct Biomater. 2018;9(1):11.
   PubMed Web of Science ®Google Scholar
• Wei C-C, Ge Z-Q. Influence of electrolyte and poloxamer 188 on the aggregation kinetics of solid lipid nanoparticles (SLNs). Drug Dev Ind Pharm. 2012;38(9):1084–1089.
   PubMed Web of Science ®Google Scholar
• Saez V, Souza I, Mansur C. Lipid nanoparticles (SLN & NLC) for delivery of vitamin E: a comprehensive review. Int J Cosmet Sci. 2018;40(2):103–116.
   PubMed Web of Science ®Google Scholar
• Makoni PA, Wa Kasongo K, Walker RB. Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics. 2019;11(8):397.
   PubMed Web of Science ®Google Scholar
• Shazly GA, Alshehri S, Ibrahim MA, et al. Development of domperidone solid lipid nanoparticles: in vitro and in vivo characterization. AAPS PharmSciTech. 2018;19(4):1712–1719.
   PubMed Web of Science ®Google Scholar
• Neves AR, Lúcio M, Martins S, et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013;8:177–187.
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95(3):627–638.
   PubMed Web of Science ®Google Scholar
• Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018;133:285–308.
   PubMed Web of Science ®Google Scholar
• Mishra A, Imam SS, Aqil M, et al. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation. Drug Deliv. 2016;23(4):1486–1494.
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Truong DH, et al. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech. 2014;15(6):1509–1515.
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Shalaby K, Badran MM, et al. Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. Int J Pharm. 2018;550(1–2):359–371.
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Janga KY. Lipid nanoparticles of zaleplon for improved oral delivery by Box–Behnken design: optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(7):1205–1214.
   PubMed Web of Science ®Google Scholar
• Alam M, Najmi AK, Ahmad I, et al. Formulation and evaluation of nano lipid formulation containing CNS acting drug: molecular docking, in-vitro assessment and bioactivity detail in rats. Artif Cells Nanomed Biotechnol. 2018; 46(Suppl. 2):46–57.
   PubMedGoogle Scholar
• Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1–2):232–243.
   PubMedGoogle Scholar
• Elmowafy M, Samy A, Raslan MA, et al. Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation. AAPS PharmSciTech. 2016;17(3):663–672.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Dev Ther. 2015;9:5269.
   PubMed Web of Science ®Google Scholar
• Shevalkar G, Vavia P. Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe. J Drug Deliv Sci Technol. 2019;53:101211.
   Web of Science ®Google Scholar
• Fathi HA, Allam A, Elsabahy M, et al. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B. 2018;162:236–245.
   PubMed Web of Science ®Google Scholar